The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; A review

Acta Oncologica

Volumn 51, Issue 4, 2012, Pages 433-440

  Torfoss, Dag ^a,b,c   Høiby, Ernst Arne ^d   Holte, Harald ^a,b   Kvaløy, Stein ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFTAZIDIME; CEPHALOSPORIN; CLOXACILLIN; FLUCONAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PENICILLIN G; TOBRAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; DOSAGE SCHEDULE COMPARISON; DRUG POTENTIATION; EMBASE; FEBRILE NEUTROPENIA; HUMAN; LEUKEMIA; LYMPHOMA; MEDLINE; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; NORWAY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; NEUTROPENIA; NORWAY; PENICILLIN G;

EID: 84859735505     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.633931     Document Type: Review

References (29)

1. Statens Helsetilsyn. Bruk av antibiotika i sykehus. Smittevernloven. Håndbok (in Norwegian). Oslo: Statens Helsetilsyn; 2001. IK-2737.
2. NORM/NORM-VET 2010. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø /Oslo: NORM, 2010. Available from: www. antibiotikaresistens.no
3. Nasjonal strategi for forebygging av infeksjoner i helsetjenesten og antibiotikaresistens (2008 - 2012). Helse- og omsorgsdepartementet (in Norwegian); publikasjonsbestilling@dss.dep.no
4. Frøl and SS, Myrvang B, Evensen S, Lingaas E. Monoterapi med ceftazidim hos pasienter med akutt leukemi og granulocytopeni. Erfaringer fra Rikshospitalet (in Norwegian). Norsk Ceftazidim Symposium. Oslo: Glaxo; 1990. p. 45 - 50.
5. Hammerstrøm J, Jacobsen T. Bakteriemi ved granulocytopenimikrobiologi og empirisk antibiotikabehandling (in Norwegian). Tidsskr Nor Legeforen 1998;118:4370-5.
6. Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B. Empirisk antibiotikabehandling hos pasienter med akutt myelogen leukemi (in Norwegian). Tidsskr Nor Legeforen 1999;119:35-8.
7. Hammerstrøm J, Roym AL, Gran FW. Bakteriemi ved maligne blodsykdommer (in Norwegian). Tidsskr Nor Legeforen 2008;128:1655-9.
8. Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Meyer P, et al . A multi-centre prospective study of febrile neutropenia in Norway: Microbiological fi ndings and antimicrobial susceptibility. Scand J Infect Dis 2005;37:455-64.
9. Torfoss D, Høi by EA, Tangen JM, Holte H, BøK, Meyer P, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial. J Antimicrob Chemother 2007;59:711-7.
10. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
11. Stabell N, Nordal E, Stensvold E, Wiger Gammelsrud K, Lund B, Taxt A, et al. Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2008;40:301-7.
12. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56 - 93.
13. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-89.
14. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Betalactam versus beta-lactam - aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2002;CD003038.
15. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993;29A:S6 - 10.
16. Sonne M, Jawetz E. Combined action of carbencillin and gentamicin on Pseudomonas aeruginosa in vitro. Applied Microbiol 1969;17:893-6.
17. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa . Int J Antimicrob Agents 2003;21:8-12.
18. Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamicin sulphate therapy. Cancer 1972;29:1697-701.
19. Bodey GP, Rodriguez V. Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer 1973;9:435-41.
20. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbencillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284: 1061-5.
21. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
22. Keating MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides - comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbencillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979;58:159-70.
23. de Man P, Verhoeven BAN, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000;355:973-8.
24. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and lactam combination therapy versus lactam monotherapy on the emergence of antimicrobial resistance: A metaanalysis of randomized, controlled trials. Clin Infect Dis 2005;41: 149-58.
25. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: Results of the ESAC retrospective data collection (1997 - 2002). J Antimicrob Chemother 2006;58: 159-67.
26. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033-48.
27. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999;96:1152-6.
28. Freundlich M, Thomsen RW, Pedersen L, West H, Schø nheyder C. Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: A Danish hospital-based cohort study. J Antimicrob Chemother 2007;60:1115-23.
29. Leibovici L, Paul M. Aminoglycoside/lactam combinations in clinical practice. J Antimicrob Chemother 2007;60:911-2.